Pylarify (piflufolastat f 18) injection
Ended Awarded Last action
- Contract number
- 36C24825N0004
- Awardee
-
Progenics Pharmaceuticals Inc. UEI YLYKVRPCTCR3 Part of Lantheus Holdings, Inc.
- Awarding agency
-
Veterans Integrated Service Network 8
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $1,129,529
Award facts
- Contract value 100% obligated
- $1,129,529.36 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- North Billerica, Billerica, MA 01862, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $498,003 | |
| Original award | $631,526 |
About this award
The Department of Veterans Affairs, Veterans Integrated Service Network 8, awarded a $1.13 million firm fixed-price call under a Blanket Purchase Agreement to Progenics Pharmaceuticals Inc. (a division of Lantheus Medical Imaging, Inc.) on October 1, 2024, for the supply of PYLARIFY (piflufolastat F-18) injection. This modification adds quantities to an existing BPA vehicle under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The contract carries no set-aside designation and is scheduled for completion by September 30, 2025, with performance occurring in North Billerica, Massachusetts. PYLARIFY is a radioactive diagnostic imaging agent used in positron emission tomography (PET) scans for the detection and localization of prostate cancer in patients undergoing diagnostic imaging procedures at VA medical centers.
This award supports the VA's medical imaging programs across its network of healthcare facilities. Progenics Pharmaceuticals, as a specialized radiopharmaceutical supplier operating under its parent company Lantheus Holdings, Inc., maintains multiple significant indefinite delivery vehicles with the VA and Defense Health Agency, including a substantial Federal Supply Schedule contract with a $290 million ceiling value through March 2030. The BPA call mechanism enables efficient procurement of critical radiopharmaceuticals to support diagnostic oncology imaging capabilities across VA medical centers nationwide, ensuring continuity of care for veteran patients requiring prostate cancer diagnostic imaging services.
Quick answers
Who was awarded contract 36C24825N0004?
36C24825N0004 was awarded to Progenics Pharmaceuticals Inc. by Veterans Integrated Service Network 8 (Veterans Health Administration) on October 1, 2024.
How much is contract 36C24825N0004 worth?
The government has obligated $1,129,529 on 36C24825N0004.
Is contract 36C24825N0004 an order under another contract?
Yes. 36C24825N0004 is a BPA call under 36F79719D0170-36C24824A0038, a blanket purchase agreement, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24825N0004 competed?
The extent of competition for 36C24825N0004 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award